EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Nanotherapeutics in Kidney Disease

Amir Roointan iD, Rong Xu iD, Simon Corrie iD, Christoph E Hagemeyer iD, Karen Alt iD

Journal of the American Society of Nephrology · 2025-03 · 36 (3) · 500-518

DOI: 10.1681/asn.0000000608 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 20.12.2024. Verfasst von Amir Roointan und 4 weiteren Autor:innen. Beteiligte Einrichtung: NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria, Austral…. Hauptthemen laut MEDLINE: Kidney Diseases, Nanomedicine. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment and management of kidney diseases present a significant global challenge, affecting over 800 million individuals and necessitating innovative therapeutic strategies that transcend symptomatic relief. The application of nanotechnology to therapies for kidney diseases, while still in its early stages, holds transformative potential for improving treatment outcomes. Recent advancements in nanoparticle-based drug delivery leverage the unique physicochemical properties of nanoparticles for targeted and controlled therapeutic delivery to the kidneys. Current research is focused on understanding the functional and phenotypic changes in kidney cells during both acute and chronic conditions, allowing for the identification of optimal target cells. In addition, the development of tailored nanomedicines enhances their retention and binding to key renal membranes and cell populations, ultimately improving localization, tolerability, and efficacy. However, significant barriers remain, including inconsistent nanoparticle synthesis and the complexity of kidney-specific targeting. To overcome these challenges, the field requires advanced synthesis techniques, refined targeting strategies, and the establishment of animal models that accurately reflect human kidney diseases. These efforts are critical for the clinical application of nanotherapeutics, which promise novel solutions for kidney disease management. This review evaluates a substantial body of in vivo research, highlighting the prospects, challenges, and opportunities presented by nanotechnology-mediated therapies and their potential to transform kidney disease treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney DiseasesNanomedicineHumansAnimalsDrug Delivery SystemsNanoparticlesNanoparticle Drug Delivery SystemForecasting

Substanzen

Nanoparticle Drug Delivery System

Autor:innen und Institutionen

  • NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • NanoTheranostics Laboratory, Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Chemical and Biological Engineering, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Amir Roointan, Rong Xu, Simon Corrie, Christoph E Hagemeyer, Karen Alt

Zitieren

APA

Roointan, A., Xu, R., Corrie, S., Hagemeyer, C. E., & Alt, K. (2025). Nanotherapeutics in Kidney Disease. Journal of the American Society of Nephrology, 36(3), 500-518. https://doi.org/10.1681/asn.0000000608

Vancouver

Roointan A, Xu R, Corrie S, Hagemeyer CE, Alt K. Nanotherapeutics in Kidney Disease. Journal of the American Society of Nephrology. 2025;36(3):500-518. doi:10.1681/asn.0000000608

BibTeX
@article{Roointan2025,
  author = {Roointan, Amir and Xu, Rong and Corrie, Simon and Hagemeyer, Christoph E and Alt, Karen},
  title = {Nanotherapeutics in Kidney Disease},
  journal = {Journal of the American Society of Nephrology},
  year = {2025},
  volume = {36},
  number = {3},
  pages = {500--518},
  doi = {10.1681/asn.0000000608}
}
Kostenlos starten →